65th ASH Annual Meeting & Exposition: 802. Chemical Biology and Experimental Therapeutics: Poster III

Symposia: Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Poster

Halls G-H (San Diego Convention Center)

Adding Hetrombopag to Cyclosporine a to Patients with Newly Diagnosed Transfusion-Dependent Non-Severe Aplastic Anemia—a Prospective Phase 2 Study

Shupei Shen¹^*, Zhuxin Zhang²^*, Junling Zhuang, MD, PhD³, Qinglin Hu, M.D.⁴^*, Miao Chen⁵^* and Bing Han, MD, PhD⁶^*

¹Chinese Academe of Medical Science, Peking Union Medical College Hospital, Beijing, China
²Peking Union Medical College Hospital, Beijing, AL, China
³Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⁴Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing, China
⁵Peking Union Medical College Hospital,Chinese Academy of Medical Sciences, Beijing, China
⁶Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, AL, China

5006

Functional and Morphological Characterization of RBCs Loaded with Factor IX Conjugated with an Anti-Glycophorin Ā Antibody

Alina D. Peshkova, PhD, MSc¹, Taylor V. Brysgel¹^*, Parth Mody¹^*, Jia Nong, PhD¹^*, Zhicheng Wang, PhD¹^*, Jacob W. Myerson, PhD¹^*, Rustem I. Litvinov, MD, PhD²^*, John W. Weisel, PhD²^*, Vladimir R. Muzykantov, MD, PhD¹^*, Patrick M. Glassman, PhD³^* and Oscar A. Marcos-Contreras, PhD¹^*

¹School of Medicine, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA
²School of Medicine, Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA
³School of Pharmacy, Department of Pharmaceutical Sciences, Temple University, Philadelphia, PA

5007

Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia

Ankita Srivastava¹^*, Caroline A. Heckman, PhD^{1,2,3,4,5,6,7}, Juho Jalmari Miettinen, PhD³^* and Olivier Harismendy, PhD⁸^*

¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
²Institute for Molecular Medicine Finland, Institute For Molecular Medicine Finland FIMM, Helsinki, Finland
³Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
⁴Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
⁵Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
⁶Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
⁷iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki, Finland
⁸Translational Data Science and Computational Biology, Zentalis Pharmaceuticals, San Diego, CA

5008

Development and Efficacy of a Novel Bromodomain and Extraterminal Domain Degrader K-256 in MYC/BCL2-Related Lymphoma

Kastuya Furukawa, MD¹^*, Kazuyuki Shimada¹, Masahiro Esaki, PhD²^*, Kentaro Tanaka²^*, Keisuke Yamamoto³^*, Kiyotoshi Mori⁴^* and Hitoshi Kiyoi, MD, PhD⁵

¹Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
²Research Unit, R&D Division, Kyowa Kirin Co, Shizuoka, Japan
³Administration department, Kyowa Kirin, Inc, La Jolla California
⁴Research Unit, R&D Division, Kyowa Kirin Co, Tokyo, Japan
⁵Nagoya University Graduate School of Medicine, Nagoya, Japan

5009

MALT1 Protease Inhibition Overcomes BTK Inhibitor Resistance and Shows Synergistic Activity with Venetoclax in Models of B Cell Lymphoma and Leukemia

Joshua Plotnik¹^*, Velitchka Bontcheva²^*, Colleen Dowell²^*, Christine Will, MS³^*, Jun Chen, MD, PhD²^*, Adam Richardson²^*, Ryan McClure²^*, Paul Jung²^*, Lan Pham⁴^*, Andrew Souers, PhD², Jonathan Meulbroek²^* and William Pappano³^*

¹Oncology Discovery Research, Abbvie, North Chicago, IL
²Abbvie, North Chicago, IL
³AbbVie Inc., North Chicago, IL
⁴AbbVie, South San Francisco, CA

5010

STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3-Mutated (mut) Acute Myeloid Leukemia (AML)

Yi Zhang^1,2^*, Wenwen Wei¹^*, Bin Zhang, PhD², Jie Sun¹^*, Dandan Zhao²^*, Fang Chen²^*, Yongfang Xu²^*, Yu Qian¹^*, Yanchun Zhao¹^*, Yutong Zhou¹^*, Wanhong Xu³^*, Xiaoying Zhang³^*, Long Mao⁴^*, Guido Marcucci, MD², Xiao Xu⁴^* and Jie Jin, MD¹

¹Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
²Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
³Hangzhou ACEA Pharmaceutical Research Co., Ltd, Hangzhou, China
⁴ACEA Therapeutics Inc, San Diego

5011

Novel Therapeutics Targeting Acute Myeloid Leukemia (AML) Stem Cells Identified through High-Throughput Screening

Isabella Iasenza, BSc^1,2, Safia Safa³^*, Frederic Barabe, MD⁴, Sonia Cellot, MD, PhD⁵^*, Brian T. Wilhelm, PhD, BSc³^* and Kolja Eppert, PhD^6,7^*

¹Department of Medicine, McGill University, Montreal, QC, Canada
²Division of Experimental Medicine, Research Institute of the McGill University Health Centre, Brossard, QC, Canada
³Institute for Research in Immunology and Cancer of the University of Montreal, Montreal, QC, Canada
⁴Hôpital de l'Enfant-Jésus, Division of Hematology and Medical Oncology, CHU de Québec - Université Laval, Québec, QC, Canada
⁵Department of Pediatric Hematology Oncology, Sainte-Justine University Health Center, Montreal, QC, CAN
⁶Division of Experimental Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
⁷Department of Pediatrics, McGill University, Montreal, QC, Canada

5012

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

Ye Seul Lim¹^*, Na-Rae Jeong¹^*, Sun-Mi Yoo²^*, Han Wool KIM¹^*, Song Hee Lee, PhD¹^* and Dong-Wook Kim, MD, PhD³

¹Ubix therapeutics, Seoul, Korea, Republic of (South)
²Ubix therapeutics, Seoul, South Korea
³Uijeongbu Eulji Medical Center, Uijeoungbu-si, Korea, Republic of (South)

5013

Transient CDK9 Inhibition with AZD4573 Effectively Induces Apoptosis in Burkitt Lymphoma As a Monotherapy in Pre-Clinical Models

Danielle S Potter¹^*, India Ott¹^*, Jamal Saeh²^*, Stephen Fawell¹^*, Lisa Drew, PhD³^* and Justine Roderick-Richardson¹^*

¹Early Oncology R&D TDE, AstraZeneca, Waltham, MA
²Hematology, Oncology R&D, AstraZeneca, Waltham, MA
³AstraZeneca, Waltham, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH